Diet, Cardiometabolic Risk (CM) and Menopause Symptoms
Metabolic Syndrome, Protection Against, Menopause
About this trial
This is an interventional treatment trial for Metabolic Syndrome, Protection Against focused on measuring menopause, peri-menopause, post-menopause, vasomotor symptoms, cardiometabolic risk, Mediterranean Diet, MedDiet, Ultimate Cholesterol Lowering Plan, UCLP, Portfolio diet, diet quality
Eligibility Criteria
Inclusion Criteria: over the past year presented with any of the following Irregular periods or no periods at all Night sweats Hot flushes Sleeplessness Brain fog Increased anxiety Joint pain Changes to hair or skin Exclusion Criteria: Ever had an eating disorder Ever diagnosed with cardiovascular disease or type 2 diabetes Ever diagnosed with kidney disease Current smoker Triglyceride levels of ≥ 5.7 mmol/L at baseline Glucose levels of ≥ 7 mmol/L at baseline Diastolic blood pressure of ≥ 100 mmHg at baseline Systolic blood pressure of ≥ 160 mmHg at baseline
Sites / Locations
- University of ChesterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
A (Med/UCLP)
B (ULCP/Med)
Following the Mediterranean Diet for six weeks, then following the Ultimate Cholesterol Lowering Plan for six weeks. Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12. Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12.
Following the Ultimate Cholesterol Lowering Plan for six weeks, then following the Mediterranean Diet for six weeks. Food diaries collected at baseline, week 2, week 4, week 6, week 8, week 10, week 12. Cardiometabolic risk markers, menopause symptoms and physical activity collected at baseline, week 6, week 12.